Have a personal or library account? Click to login

Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports†

By:
Open Access
|Jul 2019

Abstract

Objective

Cytokine release syndrome (CRS) and tumor lysis syndrome (TLS) that occur after chimeric antigen receptor T (CAR-T) cells are reinfused, which severely affect the survival and prognosis of patients. Although several articles have reported on the care of CAR-T cell immunotherapy, the quality of the study and the effectiveness of holistic nursing interventions have not been systematically reviewed. The purpose of this study was to systematically evaluate the existing holistic nursing interventions of CAR-T cell immunotherapy.

Methods

A literature search for keywords was performed in PubMed, EMBASE, the Cochrane Library, CNKI, CBM, and Wanfang Data from its inception until January 2018. Studies were deemed eligible if they comprised patients with tumor receiving CAR-T cell immunotherapy, described the holistic nursing process, and were published in Chinese and English.

Results

A total of 6 articles on holistic nursing interventions of CAR-T cell immunotherapy are reported, and the nursing methods and results of each article are analyzed. The quality of the studies included was medium. All nursing measures were considered effective.

Conclusions

Holistic nursing programs reduce the incidence of CRS and TLS and improve the quality of life of cancer patients.

DOI: https://doi.org/10.2478/FON-2019-0014 | Journal eISSN: 2544-8994 | Journal ISSN: 2097-5368
Language: English
Page range: 87 - 95
Submitted on: Oct 3, 2018
Accepted on: Dec 22, 2018
Published on: Jul 10, 2019
Published by: Shanxi Medical Periodical Press
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Xu Zhang, Di Sun, Gui-Chun Jiang, published by Shanxi Medical Periodical Press
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.